Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The offers underline Novo Nordisk’s interest in expanding beyond diabetes and into the rare diseases market.
The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.
Rumors that Acorda was considering a sale drove company stock up about 12 percent on Friday, Jan. 5, to hit $23.55.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Xinogen will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
The nearly 100-year-old medical-device business manufactures prosthetics and orthotics such as foot inserts and knee braces.
The listing of a minority of the unit, which makes X-ray and MRI machines, is set to take place in the first half of 2018.
Three biotech companies want to start out the new year with a new start.
Both companies are noted for growth through acquisition, and 2017 has been a very big year for LabCorp.
The group has bought 11 businesses in the past seven years.